SBI-425

• Description:

  SBI-425 is an orally active and potent TNAP (tissue-nonspecific alkaline phosphatase) inhibitor (IC50=16 nM) . SBI-425 inhibits TNAP in the vasculature, improving cardiovascular parameters and survival[1][2].

• UNSPSC:

  12352005

• Target:

  Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/sbi-425.html

• Purity:

  99.40

• Solubility:

  DMSO : 86.67 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC(NS(=O)(C2=CC(Cl)=CC=C2OC)=O)=CN=C1)N

• Molecular Formula:

  C13H12ClN3O4S

• Molecular Weight:

  341.77

• References & Citations:

  [1]Pinkerton AB, et al. Discovery of 5- ((5-chloro-2-methoxyphenyl) sulfonamido) nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor. Bioorg Med Chem Lett. 2018 Jan 1;28 (1) :31-34.|[2]Sheen CR, et al. Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. J Bone Miner Res. 2015 May;30 (5) :824-36.|[3]Brichacek AL, et al. Systemic inhibition of tissue-nonspecific alkaline phosphatase alters the brain-immune axis in experimental sepsis. Sci Rep. 2019 Dec 11;9 (1) :18788.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1451272-71-1]